Ionizing radiation/Mutant p53/Radiosensitivity/Transformant/Saos-2 cells
We have constructed an in vitro system to examine how p53 mutants affect radiosensitivity. Mutations of p53 were made using in vitro mutagenesis, and mutant cDNAs were introduced into the human osteosa rcoma cell line, Saos-2, which is devoid of endogenous p53. For wild type p53, both the expression plasmid and a regulation plasmid (LacSwitch system) were transfected into the cells. The radiosensitivities of clones of mutant p53 and wild type p53 were examined. Transformants of wild type p53 had increased radiosensi tivity. The induction of wild type p53 protein by addition of IPTG did not significantly increase radiosensi tivity. A mutation at codon 123 also increased radiosensitivity. Mutations at codons 143, 175, and 273 did not alter radiosensitivity.
INTRODUCTION
Mutation of the p53 gene is the most common genetic alteration observed in human can cersl'2) . p53 is a tumor-suppressor gene and plays an important role in neoplastic development' 4) Normal p53 gene product accumulates after ionizing irradiation (IR), and causes G I arrest or promotes cell death through an apoptotic pathway5-7). p53 in cells can either increase or decrease cell survival. Whether or not cancer cells are resistant or sensitive to IR is an important consider ation in radiotherapy. It has been widely reported that cells with mutant p53 are more resistant to IR or DNA-damaging agents"'). On the other hand, there have been reports of cells with mutant p53 that are sensitive to IR and anticancer drugs12,13). The specific mutations were not discussed in these reports. p53 mutants have different properties according to the mutation positions. For example, Crook et al. reported that, using a large series of p53 mutants, not all transcriptionally active mutants retained the ability to suppress transformation in primary rodent cells, but two tumor-derived point mutations displayed both transforming and transactivating activity"). Some mutant p53 genes do not merely induce the functional equivalent of p53 loss I'). Radiosensitivity of cells may depend on the type of mutation of p53. To determine which mutations of p53 affect radiosensitivity, we made four mutations of p53 at codons 123, 143, 175 and 273. Mutations at codons 175 and 273 are hot spot mutations and localized in conserved regions IV and V, respectively. Codon 123 is in conserved region III and codon 143 is adjacent to this region. We transferred these mutant p53 DNA to the human osteosarcoma cell line, Saos-2, which is null for p53, and obtained stable transformants. The effect of these mutations on radiosensitivity was examined.
MATERIALS AND METHODS

Cell culture
Saos-2 cell line (RCB0428: Riken Cell Bank) was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). The transformants were se lected in medium containing 100 Mg ml-' of hygromicin or 400 pg ml-' of G418.
Plasmids
The LacSwitch inducible mammalian expression system (Stratagene, La Jolla, CA., USA) was used. The expression plasmid was pOP13CAT, and the CAT gene was replaced by genes of a mutant or wild type p53 at a Not I site. Saos-2 cells were transfected with 2 pg of expression plasmid using the calcium phosphate precipitation method"). A plasmid of p3' SS, expressing the lac I gene coding the Lac repressor protein, was used for a regulation plasmid. For wild type p53 transfection, both the expression plasmid and regulation plasmid were co-transfected into the cells. The expression of the wild p53 gene was suppressed by the Lac repressor. Wild type p53 transformants were induced to express p53 by the addition of IPTG to the media. PCR analysis for cDNA of p53
Primer pairs encompassed a 1,041 by fragment (from Exonl to Exon 9) specific for p53. Total DNA was isolated with a DNA extraction kit (Stratagene, La Jolla, CA, USA). One µg of DNA was added to the PCR reaction mixture. Thirty cycles of PCR amplification were per formed with the parameters of 93°C, 55°C, and 72°C for 1 min, 1 min, and 2 min, respectively. The amplified products were analyzed by electrophoresis on a 1 % agarose gel and detected by ethidium bromide staining.
Western blotting for protein of p53
Total protein was extracted as described previously"). Thirty µg of protein was subjected to Western blotting analysis. Anti-p53 monoclonal antibody (Anti-Human p53 Oncoprotein; Upstate Biotechnology, Inc., Lake Placid, NY, USA) was used. Protein levels were analyzed using enhanced chemiluminescence (Amersham).
Radiation treatment and survival studies Cells were irradiated with 200 kV X-rays (Toshiba X-ray machine; Tokyo, Japan) at a dose rate of 0.308 Gy/min at room temperature. Confluent cultures incubated in 10-cm tissue culture dishes were trypsinized immediately after irradiation and plated onto a 10-cm dish at densities expected to yield about 50 clonogenic cells. After 25-31 days, colonies were examined to calcu late the surviving fraction. Wild type p53 transfectants ware supplemented with IPTG in the medium 24 h prior to the experiments at a final concentration of 5 mM. After irradiation, cells were trypsinized and plated onto dishes with 5 mM IPTG. The medium was changed to remove IPTG 48 h after incubation, and colonies were examined four weeks later. Three replicate plates per experiment were used for each survival point, and the experiments were repeated at least three times. The results on survival were calculated as mean ±SE, and comparison between values were statistically analyzed by the Student's t-test.
RESULTS
Isolation of clones expressing mutant or wild p53
For mutant p53 (mutations at codons 123, 143, 175, 273), p53 expression plasmids were directly introduced into Saos-2 cells, and 12 clones were obtained for each mutant. As we were unable to create a wild type p53 clone by directly introducing an expression plasmid, we first transferred a plasmid of p3'SS, which expresses the lac I gene encoding the Lac repressor protein, to Saos-2 cells to control the expression of wild type p53. Then, a wild type p53 expression plasmid was introduced, and we obtained one clone. PCR was performed using primers from Exon 1 and Exon 7 in p53 to check for wild type or mutant p53 cDNA. Seventeen clones pro duced PCR products, one clone for 123A, 6 clones for 143A, 6 clones for 175H, and 3 clones for 273H (data not shown). The clone of wild type also produced PCR product. Western blotting was performed to determine p53 protein expression. Nine clones had p53 cDNA and expressed p53 protein, one clone for 123A, 2 clones for 143A, 2 clones for 175H, and 3 clones for 273H (data not shown). The wild type clone also produced p53 protein. We further examined one typical clone of each mutant. Fig. 1 shows the results of PCR. PCR products of about 1 kbp were ob tained from clones of mutants or wild type p53 but not from the pOPl3 vector control clone. Fig  2- A shows the results of western blotting. The mutants of 175H and 273H had dense blots of p53 protein, while the mutats of 123A and 143A had only thin bands. Fig 2-B shows that wild type p53 protein was induced by the addition of 5 mM IPTG to the medium after a 24 h incubation. A small amount of p53 protein was observed at 0 h incubation. This indicates that the LacSwitch system is leaky and a small amount of p53 protein is produced in uninduced wild type p53 transformants. The doubling time of the wild type p53 transformant (58 h) was longer than that of Saos-2 (41 h). This may also be caused by low levels of leaky wild type p53 protein expression. After the addition of 5 mM IPTG to the medium, the doubling time of the wild type p53 transformant almost doubled (106 h) (data not shown). 
Radiosensitivity in each transformant
Confluent cells were used for X-ray irradiation. The doubling time of the wild type p53 transformants were longer than that of Saos-2, and wild type p53 transformants had a reduction in S phase (from 18% to 8%) and a increase in GO/G1 phase (from 68% to 79%) after 24 h incubation with 5 mM IPTG (data not shown). Then, the confluent condition seems to be useful to adjust the condition of cells for the X-ray irradiation. Figure 3 shows the IR dose-survival curves of the parental Saos-2 cells, control pOPI3 vector transformants, wild type, and transformants of 123A, 143A, 175H, and 273H. Wild type p53 transformants were more sensi tive to IR than parental cells both with or without induction by IPTG (p < 0.005 at 6 Gy and p < 0.01 at 4 Gy). There was no significant difference in the survival rate with or without IPTG induction. The transformants of 123A were more sensitive to IR than parental cells (p < 0.005 at 6 Gy and p < 0.025 at 4 Gy). Each transformant of 143A, 175H, and 273H exhibited similar radiosensitivities as parental Saos-2 cells or the control transformants. We also examined the radiosensitivities of other p53 mutant clones (one clone for 143A, one clone for 175H and two clones for 273H), and they also exhibited similar radiosensitivities as mutant p53 transformants (p > 0.05 at 6 Gy, data not shown). 
DISCUSSION
p53 plays an important role in the sensitivity of tumor cells to IR. Normal p53 acts as guard ian of the genome by promoting G1 arrest and repairing DNA damage's), and also kills cells by apoptosis19). p53-dependent signal transduction is induced by stress including IR20). IR induced tumors and mutation of p5321). The p53 gene is commonly mutated in human cancer, and the mutation points are widespread throughout the gene. Of about 6.5 million cancer cases world wide each year, 2.4 million tumors are estimated to contain a p53 mutation22). It is important to determine which mutations affect the sensitivity of tumor cells to IR, because sensitivity of tumor cells to IR has substantial clinical consequences in the treatment of cancer.
We made stable transformants of wild type p53 and four kinds of p53 mutants at codons 123, 143, 175 and 273 for determination of which p53 mutations affect radiosensitivity. Wild type p53 transformants were more sensitive to IR than parental cells (Fig. 3) , which may indicate that wild type p53 cells are sensitive to IR and the cells with p53 loss are resistant to IR. There was no significant difference in sensitivities between parental cells, Saos-2 and transformants with the 143A, 175H, or 273H mutation (Fig. 3) , which indicates that the effect of the loss of p53 is identical for all of these mutations. These results coincide with reports where cells with mutant p53 were more resistant to IR than wild type p53 cells"', 11> The 123A mutant was more sensitive to IR than parental cells (Fig. 3) , and had a similar degree of sensitivity as wild type p53 cells. There is no significant difference in the survival rates of wild type p53 transformants with or without IPTG induction. This may mean that the small amount of p53 producied by leaky expres sion in the wild type transformant (Fig. 2-B) were enough to alter radiosensitivity.
The density of the p53 protein blots (Fig. 2-A) may depend on the half life of the protein. These results are in accord with reports that p53 protein with mutations at 175H or 273H have long half lives (3.6-6.4 h for 175H and 7 h for 273H), and the p53 protein with a 143A mutation has a shortened half life (1.5-2 h)23>.
We examined 4 mutants of p53 (123A, 143A, 175H, and 273H) for radiosensitivity and found their radiosensitivities differed. We previously examined the sensitivity of wild type p53 and mutant p53 transformants (123A, 143A, 175H and 273H) to commonly used anticancer drugs, nimustine (ACNU), cisplatin (CDDP), adriamicin (ADR) and bleomicin (BLM)24). Transfectants with wild type p53 or mutant 123A were significantly more sensitive to ACNU than transfectants with pOPI3. This tendency corresponds well with our results on IR irradiation. Mutation of 123A seems to alter the sensitivity to anticancer drugs or IR irradiation as compared with mutations at 143A, 175H and 273H. The 123A mutant resembles wild type p53 in sensitiv ity to CDDP, ACNU, BLM241 and IR irradiation.
As the positions of p53 mutations are spread widely throughout the gene, and the radiosen sitivity of cells depends on the position of p53 mutation, it seems to be important to check the mutation position of p53 in tumor cells for predictive assays for radiotherapy.
